RxDoctor Payments DataLook up a doctor →

Andrew Lee, MD

Dermatology · Elkin, NCNPI 1518154889

Payments from drug & device makers

$702,436in general payments, 2019–2025

Across 1,169 payments — averaging $600.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$263K
  • Amgen$102K
  • Dermavant Sciences, Inc.$97K
  • Sanofi$65K
  • Regeneron Healthcare Solutions, Inc.$55K
  • Galderma Laboratories, L.p.$47K
  • plus $73K from 19 others

What the payments were for

  • Consulting fees$15,6802%
  • Speaking & faculty fees$626,21089%
  • Travel & lodging$37,6025%
  • Food & beverage$22,3713%
  • Education$5730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$702,436 in reported general payments places this provider in the 95th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$252,716
Medicare patients
1,000
Services billed
3,938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa72$1,628,956
Humira(Cf) PenAdalimumab51$768,781
Dupixent PenDupilumab168$671,723
Cosentyx Unoready PenSecukinumab35$385,413
AdbryTralokinumab-Ldrm17$64,324
Acitretin15$6,859
Fluorouracil91$6,693
Clobetasol Propionate160$5,789
Betamethasone Dipropionate148$5,637
Ketoconazole340$4,653
Triamcinolone Acetonide346$4,192
Minocycline Hcl314$4,104
Gabapentin180$3,519
ValacyclovirValacyclovir Hcl69$1,691
Metronidazole23$1,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
LEO Pharma Inc.Adbry$332$64,32417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Elkin

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →